Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.69 |
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | CA7 | P43166 | 3/20 | 0.69 |
| ▸ | CA9 | Q16790 | 3/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.69 |
| ▸ | XDH | P47989 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | HPGD | P15428 | 6/20 | 0.62 |
| ▸ | GAA | P10253 | 5/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433281 | 1.00 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL2972630 | 0.98 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3944216 | 0.85 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29357340 | 0.85 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24412 | 0.85 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29375113 | 0.84 | KDM4E (0.72) | CA12CA1CA2CA7CA9 | |
| SCHEMBL192100 | 0.84 | KDM4E (0.72) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL31119219 | 0.83 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL945972 | 0.83 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL1223871 | 0.82 | KDM4E (0.70) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 896 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116730657-B | Cold patch asphalt mixture and preparation method thereof | 芜湖城瑞路桥建设有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-116730657-A | Cold patch asphalt mixture and preparation method thereof | 芜湖城瑞路桥建设有限公司 | 2023-09-12 | — | — | CN | claimed |
| EP-1091745-B1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS | CHILDREN S HOSPITAL LOS ANGELE (US) | 2008-10-01 | — | — | EP | claimed |
| US-20060110743-A1 | Drug evolution: drug design at hot spots | KONISHI YASUO | 2006-05-25 | — | — | US | claimed |
| WO-2002095393-A2 | DRUG EVOLUTION: DRUG DESIGN AT HOT SPOTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2002-11-28 | — | — | WO | claimed |
| JP-3042638-A | — | — | None | — | — | JP | disclosed |
| US-12612412-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12577217-B2 | 15-PGDH inhibitor | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| US-12570620-B2 | Covalent inhibitors of creatine kinase (CK) and uses thereof for treating and preventing cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-121574765-A | Lubricating grease composition for roller bearing and preparation method thereof | 廊坊市兰春润滑脂有限公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-4688751-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | Enanta Pharmaceuticals, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-1991009842-A1 | ELECTRO-OPTICAL MATERIALS AND LIGHT MODULATOR DEVICES CONTAINING SAME | ALLIED-SIGNAL INC. (US) | 1991-07-11 | — | — | WO | disclosed |
| JP-H0342638-A | ORGANIC NONLINEAR OPTICAL MATERIAL | TORAY IND INC | 1991-02-22 | — | — | JP | disclosed |
| US-4920140-A | Skin disorders | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1990-04-24 | — | — | US | disclosed |
| US-4740519-A | Benzo (b) thiophene carboxylate derivatives and pharmaceutical compositions | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1988-04-26 | — | — | US | disclosed |
| US-4190594-A | ABSORBERS OF ULTRAVIOLET RADIATION | JOHNSON & JOHNSON (US) | 1980-02-26 | — | — | US | disclosed |
| US-4150046-A | ORGANIC PIGMENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-04-17 | — | — | US | disclosed |
| US-4110246-A | OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-08-29 | — | — | US | disclosed |
| US-4108880-A | ULTRAVIOLET ABSORBERS | JOHNSON & JOHNSON (US) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570620-B2 | Covalent inhibitors of creatine kinase (CK) and uses thereof for treating and preventing cancer | CSNK1A1L, CKMT1A; CKMT1B, KHK | CA12 1623/4885CA1 3049/4885CA2 705/4885 |
| US-12577217-B2 | 15-PGDH inhibitor | PTGDR, ADH1A, ADRA1A | CA12 2443/4885CA1 1410/4885CA2 1125/4885 |
| US-12612412-B2 | Antiviral heterocyclic compounds | ZC3HAV1, NHERF1, HM13 | CA12 1107/4885CA1 2884/4885CA2 1209/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | CA12 3515/4885CA1 3047/4885CA2 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.